Summer School Webcast Series - CME (2020)
We know urology HCP's today need quality education that works with your schedule- that's why the AUA has created our Summer School Webinar Series.
The AUA Summer School Webinar Series is the perfect way for urology healthcare professionals who find themselves with unpredictable schedules and travel restrictions to find opportunities for continuing education. This series of over two dozen 90-minute live webinars will be offered twice per week, each week from May 26 through September 4.
FOLLOWING THE LIVE EVENT, SELECT COURSE WEBCASTS WILL BE RELEASED FOR CME! SEE FULL SCHEDULE BELOW:
Webcast | Date Available |
---|---|
2020 Guideline: Advanced Prostate Cancer | July 8 |
Contemporary Pharmacotherapy for OAB 2020: Monotherapy & Combined Pharmacotherapy to Optimize Treatment | July 8 |
Case-Based Discussion of AUA Non-muscle Invasive Bladder Cancer Guidelines | July 15 |
Trimodality Therapy for Management of Muscle Invasive Bladder Cancer | July 22 |
Diagnosis and Management of Localized, Locally Advanced and Advanced Kidney Cancer | July 22 |
Chemotherapy and Immunotherapy Options for Genitourinary Malignancies: | July 29 |
Refractory OAB: Tips and tricks on optimal 3rd line therapy delivery | July 29 |
Management of NMIBC: Practical Solutions for Common Problems | August 5 |
Using Shared Decision Making to Help Patients Decide on Prostate Cancer Screening and Treatment | August 12 |
AUA Guidelines: Evaluation and Management of Localized Renal Masses: A Case-Based Approach | August 12 |
Prostate Cancer Update | August 19 |
Genetic Testing in Prostate Cancer: Considerations for Urologists and Their Patients | August 21 |
Novel Agents & Concepts in the Management of Hormone Naïve & Castrate Resistant Prostate Cancer | September 2 |
Common Dilemmas in Prostate Cancer Detection and Management | September 2 |
Integrating Care for Oncology Patients: Establishing a Multidisciplinary Oncology Clinic with Advanced Therapeutics | September 9 |
Renal Cell Carcinoma: Surgical & Medical Management of High-Risk Renal Cell Carcinoma: New Paradigms for Treatment | September 9 |
See the program tab for additional details on the individual webcasts offered!
Target Audience
- Urologists
- Residents
- Advanced Practice Providers (Nurse Practitioners and Physician Assistants)
AUA 2020 Guideline: Advanced Prostate Cancer
Course Director: Michael S. Cookson, MD, MMHC
Course Faculty: Adam S. Kibel, MD; David F. Jarrard, MD; William Thomas Lowrance, MD
Contemporary Pharmacotherapy for OAB 2020: Monotherapy and Combined Pharmacotherapy to Optimize Treatment
Course Director: Eric Scott Rovner, MD
Course Faculty: Christopher R. Chapple, MD; Alan J. Wein, MD, PhD
Case-Based Discussion of AUA Non-muscle Invasive Bladder Cancer Guidelines
Course Director: Sam S. Chang, MD
Course Faculty: Christopher Anderson, MD; James Michael McKiernan, MD; Chad R. Ritch, MD; Kristen R. Scarpato, MD
Trimodality Therapy for Management of Muscle Invasive Bladder Cancer
Course Director: Adam S. Feldman, MD, MPH
Course Faculty: Jason Efstathiou, MD, PhD; Richard J. Lee, MD, PhD
Diagnosis and Management of Localized, Locally Advanced and Advanced Kidney Cancer
Course Director: W. Marston Linehan, MD
Course Faculty: Mark W. Ball, MD; Ramaprasad Srinivasan, MD, PhD; David F. McDermott, MD
Chemotherapy and Immunotherapy for Genitourinary Malignancies: A Primer for Urologists and Advanced Practice Providers
Course Director: Costas D. Lallas, MD
Course Faculty: Anne E. Calvaresi, NP; Edouard J. Trabulsi, MD
Refractory OAB: Tips and Tricks on Optimal 3rd Line Therapy Delivery
Course Director: Kathleen Chizuko Kobashi, MD
Course Faculty: Sandip Prasan Vasavada, MD; David Alan Ginsberg, MD
Management of NMIBC: Practical Solutions for Common Problems
Course Director: Kamal S. Pohar
Using Shared Decision Making to Help Patients Decide on Prostate Cancer Screening and Treatment
Course Director: Danil Victor Makarov, MD, MHS
Course Faculty: Michael John Barry, MD
AUA Guidelines: Evaluation and Management of Localized Renal Masses: A Case-Based Approach
Course Director: Steven Charles Campbell, MD, PHD
Course Faculty: Brian Robert Lane, MD, PhD; Phillip M. Pierorazio, MD; Robert G. Uzzo, MD, MBA
Prostate Cancer Update
Course Director: William J. Catalona, MD
Course Faculty: Stacy Loeb, MD; Robert Nadler, MD; Douglas Dahl, MD; Russell Szmulewitz, MD; Stanley Liauw, MD
What's New in the Management of Hormone Naïve & Castrate Resistant Prostate Cancer: A Case-based Session for Urologists, Advanced Practice Providers & Teams
Course Director: Judd W. Moul, MD, FACS
Course Faculty: Lawrence I. Karsh, MD; Evan Y. Yu, MD
Common Dilemmas in Prostate Cancer Detection and Management
Course Director: Gerald L. Andriole, Jr., MD
Course Faculty: Anthony Victor D'Amico, MD, PhD; Adam S. Kibel, MD; A. Oliver Sartor, MD
Integrating Care for Oncology Patients: Establishing a Multidisciplinary Oncology Clinic with Advanced Therapeutics
Course Director: Kelly L. Stratton, MD
Course Faculty: Kelvin A. Moses, MD, PhD; Alicia Morgans, MD, MPH; Brian Matthew Shuch, MD
Renal Cell Carcinoma: Surgical & Medical Management of High-Risk Renal Cell Carcinoma: New Paradigms for Treatment
Course Director: Benjamin R. Lee, MD
Course Faculty: A. Oliver Sartor, MD; Chandru P. Sundaram, MD, FACS, FRCS
Education Council Disclosures
AUA Office of Education Staff has nothing to disclose.
METHOD OF PARTICIPATION:
Learners will participate in this online educational activity by taking the pretest, viewing the webcast and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.
Estimated time to complete this activity: 23.50 hours
Release Date: July, 2020
Expiration Date: September, 2021
ACCREDITATION:
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION:
The American Urological Association designates this enduring material for a maximum of 23.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
OTHER LEARNERS:
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.